<DOC>
	<DOCNO>NCT00458796</DOCNO>
	<brief_summary>RATIONALE : Zoledronic acid may help decrease risk broken bone , bone pain , symptom cause bone metastasis . It may also help patient live comfortably . PURPOSE : This randomized clinical trial study different schedule zoledronic acid compare well work treat patient breast cancer spread bone .</brief_summary>
	<brief_title>Comparison Two Schedules Zoledronic Acid Treating Patients With Breast Cancer That Has Spread Bone</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare frequency time serious related event ( e.g. , fracture , radiotherapy bone , hypercalcemia malignancy , orthopedic surgery , spinal cord compression ) patient advance breast cancer metastatic bone treat bone marker-directed schedule v standard schedule zoledronic acid . Secondary - Compare quality life patient treat regimen . - Compare clinical burden skeletal complication patient . - Compare pain , performance status , analgesic use ( PPA score ) patient . - Compare incidence new bone metastases patient . - Compare overall survival patient . - Compare bisphosphonate use expenditure administration patient . OUTLINE : This open-label , randomize , control , parallel-group , multicenter study . Patients stratify accord treatment center , gender , type concurrent systemic therapy study entry ( endocrine therapy [ without trastuzumab ( Herceptin^® ) ] vs chemotherapy [ without trastuzumab ] v trastuzumab alone vs chemotherapy endocrine therapy [ without trastuzumab ] v systemic anticancer treatment ) , prior skeletal-related event ( yes v ) , duration bisphosphonate use metastatic disease prior study entry ( 4-6 month v 6-12 month ) , type metastasis present study entry ( bone v bone soft tissue v bone visceral metastasis vs bone , soft tissue , visceral metastasis ) . Patients randomize 1 2 treatment arm . - Arm I ( standard schedule ) : Patients receive zoledronic acid IV 15 minute every 3-4 week 24 month . - Arm II ( bone marker-directed schedule ) : Patients receive zoledronic acid IV 15 minute every 3-4 , 8-9 , 15-16 week ( base serum N-telopeptide : creatinine ratio ) 24 month . Quality life assess baseline 3 , 6 , 9 , 12 , 18 , 24 month . After completion study therapy , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 1,500 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Paraneoplastic Syndromes</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary breast cancer Advanced disease Radiographic confirmation bone metastasis ( ≥ 1 bone scan lesion must confirm metastatic plain radiograph CT scan/MRI ) Must receive zoledronic acid treat metastatic bone disease ( i.e. , ≥ 4 5 zoledronic acid treatment prior study entry patient receive 4 3weekly infusion , respectively ) ≥ 4 month prior study entry Any bisphosphonate treat metastatic bone disease allow provide give 12 month prior study entry No metabolic bone disease ( e.g. , Paget 's disease bone ) Osteoporosis allow No brain metastases Hormone receptor status specify PATIENT CHARACTERISTICS : Male female Menopausal status specify WHO ECOG performance status 02 Life expectancy ≥ 6 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception AST ALT ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Creatinine clearance ≥ 30 mL/min No poor venous access No concurrent active dental problem , include infection teeth jawbone ( maxilla mandibular ) No prior current diagnosis osteonecrosis jaw No cancer within past 5 year except nonmelanomatous skin cancer , carcinoma situ uterine cervix , superficial bladder cancer treat curative intent PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior bisphosphonate treatment within past 3 week No treatment systemic boneseeking radioisotope ( e.g. , strontium chloride Sr 89 , samarium Sm 153 lexidronam pentasodium ) within past 3 month No widefield ( hemibody ) radiotherapy within past 3 month Recent standardfield , localize radiotherapy allow No dental jaw surgery ( e.g. , extraction , implant ) within past 4 week No concurrent bisphosphonates No concurrent medication drug know affect bone metabolism ( e.g. , calcitonin highdose systemic corticosteroid [ &gt; 10 mg prednisolone/day equivalent ] ) Systemic oral corticosteroid allow clearly indicate condition ( e.g. , chemotherapyinduced emesis , brain metastasis , compression syndrome ) Concurrent chemotherapy , biological therapy , endocrine therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>hypercalcemia malignancy</keyword>
	<keyword>musculoskeletal complication</keyword>
	<keyword>pain</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>